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Current multiomics assay platforms facilitate systematic identification of functional entities that are mappable in a biological
network, and computational methods that are better able to detect densely connected clusters of signals within a biological network
are considered increasingly important. One of themost famous algorithms for detecting network subclusters isMolecular Complex
Detection (MCODE). MCODE, however, is limited in simultaneous analyses of multiple, large-scale data sets, since it runs on the
Cytoscape platform, which requires extensive computational resources and has limited coding flexibility. In the present study, we
implemented the MCODE algorithm in R programming language and developed a related package, which we called MCODER.
We found the MCODER package to be particularly useful in analyzing multiple omics data sets simultaneously within the R
framework. Thus, we applied MCODER to detect pharmacologically tractable protein-protein interactions selectively elevated in
molecular subtypes of ovarian and colorectal tumors. In doing so, we found that a single molecular subtype representing epithelial-
mesenchymal transition in both cancer types exhibited enhanced production of the collagen-integrin protein complex.These results
suggest that tumors of this molecular subtype could be susceptible to pharmacological inhibition of integrin signaling.
1. Introduction
Biological functions often arise from multisubunit protein
complexes, rather than a single, isolated protein [1, 2].
Many high throughput assay platforms in genomics, tran-
scriptomics, and proteomics have become standard methods
for investigating gene/protein interactions that give rise to
biological functions [3]. However, because of biological and
technical errors, these methods are hindered by a limited
signal-to-noise ratio, rendering them vulnerable to high
rates of false positives and false negatives; particularly when
discovered hits represent a single gene, protein, and so forth.
In this regard, codiscovery of hits for multiple subunits of a
protein complex in an experimental condition helpsmutually
support the significance of such findings [4]. Detection of
higher order clusters in a large network, however, is com-
putationally challenging [5]. A number of algorithms have
been developed over the past decade to tackle this problem,
including the Markov Cluster Algorithm (MCL) [6], Molec-
ular Complex Detection (MCODE) [7], DPClus [8], Affinity
Propagation Clustering (APC) [9], Clustering based onMax-
imal Clique (CMC) [10], ClusterMaker [11], and Clustering
with Overlapping Neighborhood Expansion (ClusterONE)
[12]. Many of these algorithms have been implemented in
various Cytoscape applications (CytoCluster, ClusterViz [13],
and ClusterMaker [11]), as well as in java-based applications
(C-DEVA [14]). Of these, as of February 2017, MCODE was
the most downloaded Cytoscape application within the clus-
tering category. MCODE discovers interconnected network
clusters based on 𝑘-core score: the 𝑘-core of a particular graph
(graph X) represents the maximal number of connected
subgraphs of graph X, in which all nodes are connected by 𝑘
(minimumnumber of degrees). AlthoughCytoscape is a java-
based, open source, bioinformatics software platform with
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a user-friendly graphic-user interface [15], it requires exten-
sive computational resources due to the memory restraints
of java virtual machines (Cytoscape version 3.2.1: 2 GB+
recommended). Thus, its capacity to process input networks
and graphical outputs is limited. For a computationally
intensive task, R may be a better-suited platform. R is the
most popular open source, statistical programming language,
and data analysis platform used in analysis of broad, high
throughput, and multiomics data. While the platform is
suitable for iterative analysis of large-scale data sets in batch
mode, R-based network clustering software is rare. Herein,
we describe our implementation of theMCODE algorithm in
R programming language and a related package, hereinafter
referred to asMCODER.TheMCODERpackage can be easily
integrated into custom R projects and provides powerful
and enhanced graphical output options, compared to its
Cytoscape counterpart.
The Cancer Genome Atlas projects have classified tumors
into subtypes that share distinct molecular and genetic
features. To do so, researchers have leveraged multiomics
data sets, including global and phosphoproteomic quan-
tification, as well as DNA- and RNA-level measurements.
Nevertheless, drawing associations between these subtypes
and clinically important features, such as prognosis and
therapeutic options, remains important challenges. In this
study, we intended to focus on these challenges in high-
grade serous ovarian carcinoma (HGS-OvCa) and colorectal
cancer (CRC). Currently, standard treatment for ovarian
cancer involves primary cytoreductive surgery, followed by
platinum-based chemotherapy. Only two targeted thera-
pies are clinically available for ovarian cancer, including
poly (ADP-ribose) polymerase inhibitors and angiogene-
sis inhibitors in recurrent ovarian cancer [16], although
they have been shown to offer little survival benefit. The
four molecular subtypes of HGS-OvCa are differentiated,
immunoreactive, proliferative, and mesenchymal, according
to gene content analysis within each subtype, following
transcriptome-based subtype classification [17, 18]. Of these,
the mesenchymal subtype displays the worst prognosis [19,
20]. Meanwhile, CRC has four consensus molecular subtypes
(CMSs): CMS1, CMS2, CMS3, and CMS4.TheCMS subtypes
of CRC are associated with various clinical features, such as
sex, tumor site, stage at diagnosis, histopathological grade,
and prognosis, as well as molecular features of microsatellite
status, CpG island methylator phenotype (CIMP), somatic
copy number alteration (SCNA), and enrichment of partic-
ular driver mutations. The CMS1 subtype exhibits high MSI,
high CIMP, strong immune activation, and frequent BRAF
mutation and involves an intermediate prognosis, showing
worse survival after relapse. The CMS2 subtype displays
a high degree of chromosomal instability (high SCNA),
frequent APC mutation, and good prognosis. Tumors of the
CMS3 subtype display mixed MSI, high SCNA, frequent
KRAS mutation, metabolic deregulation, and good progno-
sis. Finally, the CMS4 subtype is characterized by distinct
epithelial-mesenchymal transition (EMT) signature, high
SCNA, and the poorest prognosis. Notably, in both cancers,
mesenchymal subtype confers the worst prognosis. To gain
insights into molecular subtype-selective opportunities for
targeted therapies in ovarian and colorectal cancer, HGS-
OvCa [21] and CRC [22] data sets were analyzed using
MCODER. Both data sets contained mass-spec-based quan-
titative proteomic assay results for the well-definedmolecular
subtypes of these cancers. In particular, we aimed to identify
pharmacologically tractable protein complexes selectively
elevated within the distinct molecular subtypes of both
cancers.
2. Implementation
MCODER identifies the maximal subset of vertices inter-
connected by the minimal number of degrees (𝑘) from
an input network of nodes (genes or proteins) and edges
(pairwise interactions). Although the MCODER package
does not account for the direction of the edges when cal-
culating 𝑘-core scores and when detecting subnetworks, it
can indicate directions using arrows and display multiple
edges between a pair of nodes, which is not supported by
the original MCODE. Moreover, various graphical param-
eters provided by “igraph” (http://igraph.org/redirect.html)
can be manipulated in MCODER, facilitating customiza-
tion of the shape, size, and color of the network output.
The MCODER R package requires preinstallation of two
other packages, “sna” (Social Network Analysis) (https://
cran.r-project.org/web/packages/sna/index.html) for calcu-
lating 𝑘-cores and “igraph” for plotting figures.
The overall workflow of the present study to iden-
tify pharmacologically tractable protein complexes is pre-
sented in Figure 1. Before running MCODER, we down-
loaded the STRING database (Homo sapiens, v10.0) from
http://string-db.org: STRING is an archive of direct (phys-
ical) and indirect (functional) protein-protein interactions
[23]. We filtered low confident interactions by applying an
interaction-score cutoff (score < 0.4) to obtain 13,159 genes
with 738,312 interactions. In parallel, we downloaded and
preprocessed proteome data sets by selecting samples that
have preassigned molecular subtypes and matched normal
controls to obtain input data sets: HGS-OvCa (𝑛 = 3,329
proteins, 140 samples) and CRC (𝑛 = 3,718 proteins, 70
samples) [21, 22]. HGS-OvCa consisted of four molecular
subtypes: differentiated (𝑛 = 35 samples), immunoreactive
(𝑛 = 37 samples), proliferative (𝑛 = 34 samples), and mes-
enchymal (𝑛 = 34 samples). CRC consisted of four molecular
subtypes: CMS1 (𝑛 = 14 samples), CMS2 (𝑛 = 28 samples),
CMS3 (𝑛 = 9 samples), and CMS4 (𝑛 = 14 samples). To
identify differentially expressed proteins (DEPs) selectively
elevated in a particular molecular subtype, a one-sided 𝑡-
test was conducted iteratively within a tumor (e.g., CMS1
versus CMS2, CMS3, CMS4). After preparing differentially
expressed protein sets, we converted them into adjacency
matrices for each set, with connection information between
nodes according to the STRING database, followed by calcu-
lation of 𝑘-core values, vertex density, and vertex score. Self-
loop and duplicated connections between nodes were not
considered for the calculation. Clusters were detected with
the following parameters: minimal 𝑘-core value = 2, haircut =
TRUE, fluff = FALSE, self-loop = FALSE, node score cutoff =
0.2, depth = 20, and degree cutoff = 2. Subsequently, vertices
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Figure 1: Workflow for detecting densely connected network clusters using MCODER. See Implementation for further details.
Table 1: Comparison of computational time and memory usage
between MCODER and the MCODE Cytoscape application.
Network size Performance
MCODER Cytoscape MCODE
5K edges, 2,902 vertexes 6 s. 1m. 14 s.
100K edges, 3,786 vertexes 11 s. 3m. 44 s.
200K edges, 4,625 vertexes 19 s. 18m. 47 s.
Memory usage 0.45GB 5GB
in the clusters were annotated according to the DGI database
[24], allowing for detection of druggable DEPs.
3. Results
First, we examined the performance of MCODER (Figure 1)
in comparison to the MCODE Cytoscape application, testing
input networks of different sizes (Table 1). All tests were
performed using MacBook Pro (Mac OS X, Late 2013,
2.4-GHz Intel Core i5, 8 GB RAM). Input data sets were
prepared by random sampling of the given number of
interactions from the STRING database. We found that
both software packages returned identical protein complexes
as an output. Meanwhile, however, MCODER in the R
environment offered enhanced performance in regard to
speed and memory usage in all test settings (Table 1).
The MCODER installation package is available online at
https://sourceforge.net/projects/mcoder.
Next, for the individual molecular subtypes, we iden-
tified selectively elevated proteins under a 𝑝 value thresh-
old of 0.01: 300 proteins for differentiated, 284 proteins
for immunoreactive, 547 proteins for proliferative, and 493
proteins for mesenchymal HGS-OvCa and 236 proteins for
CMS1, 284 proteins for CMS2, 134 proteins for CMS3, and
137 proteins for CMS4 subtypes of CRC (see Supplementary
Data 1 in the Supplementary Material available online at
https://doi.org/10.1155/2017/1016305). For each of the DEP
sets,MCODER identified highly interconnected subnetworks
of protein-protein interactions. For HGS-OvCa, we detected
pharmacologically targetable clusters in three of the four sub-
types (Supplementary Data 2). In the immunoreactive sub-
type, two clusters showed connections with pharmacological
agents. The first cluster contained interferon-stimulated gene
15 (ISG15), which is a biomarker for predicting sensitivity to
irinotecan, an anticancer drug and topoisomerase I inhibitor
(Figure 2(a)). Previous studies have demonstrated that ISG15
encodes an ubiquitin-like protein conjugated to specific E3
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Figure 2: Pharmacologically targetable network clusters overexpressed in molecular subtypes of HGS-OvCa: (a, b) immunoreactive, (c, d)
proliferative, and (e) mesenchymal subtype.
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ubiquitin ligases and seems to inhibit the signaling conse-
quences of ubiquitin/26S proteasome pathways [25]. Cur-
rently, treatments with irinotecan, in combination with beva-
cizumab or cisplatin, are in clinical trials for recurrent ovarian
cancer [26]. Our findings suggest that selecting patients with
immunoreactive features might increase response rates to
irinotecan in future trials. The second cluster comprised
a chemokine signaling related protein complex, including
STAT3, which can be inhibited by RTA402, acitretin, and
atiprimod (Figure 2(b)). Previous studies have indicated that
STAT3 inhibitors, in combination with cisplatin, enhance
cisplatin sensitivity in cisplatin-resistant ovarian cancer [27,
28]. Thus, a combination of irinotecan and STAT3 inhibitors
might be plausible in treating ovarian cancers of immunore-
active subtype. In the proliferative subtype, two clusters dis-
played connections with pharmacological compounds. The
CDK2-proteasome-XPO1 cluster was enriched with pharma-
cological options, including the proteasome inhibitor borte-
zomib, which is available clinically, and CDK2 and XPO1
inhibitors, which are under active clinical trials for various
tumor types (Figure 2(c)) [29, 30]: XPO1 inhibitors have been
used to target platinum-resistant ovarian tumors [31] and
have been described as potentially inhibiting abnormal NF-
kB signaling [32]. The second DEP cluster was the tubulin
complex, in which TUBA4A can be targeted by vincristine to
blunt mitotic chromosomal separation (Figure 2(d)). Similar
to paclitaxel, a microtubule stabilizer and an antiproliferative
agent [33], vincristine may be a potential agent for the
treatment of ovarian cancer, particularly that of prolifera-
tive subtype. In the mesenchymal subtype, focal adhesion,
endocytosis, vascular smooth muscle contraction, the PI3K-
AKT signaling pathway, and so forth were identified. Of
these, the integrin-collagen complex is a pharmacologically
tractable target; various integrin signaling inhibitors include
ITGA5 inhibitors (JSM 6427, PF-04605412, Volociximab, and
Vitaxin), ITGB1 inhibitors (Volociximab, JSM 6427, R411,
Vitaxin, and PF-04605412), and an ITGAV inhibitor (L-
000845704) (Figure 2(e)). Integrin signaling is involved in
the migration, invasion, proliferation, and survival of cancer
cells [34]. Recently published studies have demonstrated
that integrins participate in maintaining cancer stem cell
populations and contribute to cancer progression and drug
resistance [35]. Although integrin inhibitors as monotherapy
agents have failed to demonstrate benefits in metastatic
ovarian tumors, possibly due to compensation by other
integrins [36], simultaneous targeting of integrin-FAK and
c-Myc signaling has been found to synergistically disrupt
tumor cell proliferation and survival in HGS-OvCa [37],
supporting the notion of combinatorial targeting of integrin
as a valid approach for treating ovarian cancer, particularly
that of mesenchymal subtype.
For CRC, MCODER identified pharmacologically tar-
getable protein complexes in three of the four CMSs (Sup-
plementary Data 2). In CMS1 subtype (MSI immune), pro-
teasome complex (similar to the HGS-OvCa proliferative
subtype) and ROCK1 signaling subnetworks were found to be
overexpressed (Figures 3(a)-3(b)). Bortezomib treatment has
been shown to induce G2-M arrest by activation of an ataxia-
telangiectasia mutated protein-cell cycle checkpoint kinase 1
pathway in colon cancer cells [38]. Combination of platelet-
derived growth factor and the ROCK inhibitor Y27632 has
been found to decrease the invasive potential of SW620
colon cancer cells [39]. In the CMS2 subtype (canonical),
tubulin complexwas found to be elevated, similar to theHGS-
OvCa proliferative subtype (Figure 3(c)). This observation
suggests that vincristine could have therapeutic effects on
CRCs of CMS2 subtype. Alternatively, or in combination
with microtubule inhibitors, Src inhibitors may also be a
plausible approach for CMS2 tumors (Figure 3(d)). The
CMS4 subtype of CRCs exhibits EMT activation and confers
the poorest prognosis. Other study groups have formerly
referred to this subtype as colon cancer subtype 3 [40] or
stem-like subtype [41]. In CMS4 tumors, we found the total
MAPK3 (ERK1) protein complex to be elevated, which is
targetable with ERK inhibitor II (Figure 3(e)). Surprisingly,
in accordance with the HGS-OvCa mesenchymal subtype,
CMS4 was also characterized by elevation of the extracellular
matrix collagen-integrin complex (Figure 3(f)): collagen in
the extracellular matrix has indeed been found to drive EMT
in CRC [42]. Thus, the collagen-integrin protein complex
may work as a molecular linchpin that, when removed,
could diminish the malignant potential of EMT tumors.
Accordingly, we suggest that therapeutic antibodies that
interrupt the signaling of integrin proteins could potentially
be utilized as therapeutic options, in combination with other
chemo- or targeted therapies, for this refractory subtype of
colon cancer.
Finally, we sought to determine whether our findings
are reproducible with other network clustering algorithms,
including ClusterONE [12] and MCL [6]. Although the
sizes of the detected clusters varied, all of the subclusters
detected by MCODER were identified by these algorithms as
well, indicating that our findings are robust across different
clustering algorithms.
4. Discussion
In this study, we implemented the network clustering algo-
rithm MCODE into the R software environment (which
we called MCODER) and demonstrated that the MCODER
package saves computational resources and time, making
it particularly suited for analyzing multiple omics data
sets. Using MCODER, we identified potential candidates
for anticancer therapy in molecular subtypes of ovarian
and colorectal cancer by detecting protein complexes that
were selectively overexpressed therein and that could be
targeted with known pharmacological agents. For HGS-
OvCa, we found that irinotecan and STAT3 inhibitors may
be candidates for the immunoreactive subtype, along with
bortezomib, CDK2, XPO1 inhibitors, and vincristine for the
proliferative subtype and integrin signaling inhibitors for the
mesenchymal subtype. For CRC, we found bortezomib and
ROCK inhibitors to be potential candidates for the CMS1
subtype, along with vincristine and Src inhibitors for the
CMS2 subtype and ERK inhibitor II and integrin signaling
inhibitors for the CMS4 subtype. Importantly, our analyses
revealed that the collagen-integrin protein complex, which
is pharmacologically tractable, is commonly overexpressed
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Figure 3: Pharmacologically targetable network clusters overexpressed in molecular subtypes of CRC: (a, b) CMS1, (c, d) CMS2, and (e, f)
CMS4.
BioMed Research International 7
in EMT subtypes of both ovarian and colorectal cancers.
Further studies are needed to determine whether pharmaco-
logical inhibition of collagen-integrin signaling blunts tumor
growth in an in vivo model of EMT cancer.
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